Drugs / Tc99m sestamibi
Tc99m sestamibi
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT05042687 | Dec 2021 → Dec 2027 expected | breast cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| — | NCT02324387 | Jun 2015 → Mar 2028 expected | breast cancer | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT01499654 | Oct 2011 → Dec 2014 | ischemic disease, myocardial infarction | Edwin Wu | Terminated | Missed primary Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01019486 Background | Nov 2009 → Dec 2011 | coronary artery disorder, type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tc99m sestamibi | “Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed...” NCT01019486 ↗3“a small catheter (tube) will be placed in a vein in the subject's arm to administer the radioactive imaging agent, Tc-99m sestamibi.” NCT01499654 ↗ |
| Known as | Cardiolite (sestamibi) | “Cardiolite (sestamibi)” NCT01019486 ↗ |
| Known as | technetium (Tc-99m) sestamibi, Cardiolite | “technetium (Tc-99m) sestamibi, Cardiolite” NCT01499654 ↗ |
| Modality | Diagnostic / imaging agent | “Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected” NCT01019486 ↗ |
| Route | Intravenous | “a small catheter (tube) will be placed in a vein in the subject's arm to administer the radioactive imaging agent, Tc-99m sestamibi.” NCT01499654 ↗ |